Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism

Title: Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism
Authors: Bartlomiej Taciak; Maciej Bialasek; Malgorzata Kubiak; Ilona Marszalek; Malgorzata Gorczak; Olha Osadchuk; Daria Kurpiel; Damian Strzemecki; Karolina Barwik; Marcin Skorzynski; Julia Nowakowska; Waldemar Lipiński; Łukasz Kiraga; Jan Brancewicz; Robert Klopfleisch; Łukasz Krzemiński; Emilia Gorka; Anna Smolarska; Irena Padzinska-Pruszynska; Małgorzata Siemińska; Jakub Guzek; Jan Kutner; Marlena Kisiala; Krzysztof Wozniak; Giacomo Parisi; Roberta Piacentini; Luca Cassetta; Lesley M. Forrester; Lubomir Bodnar; Tobias Weiss; Alberto Boffi; Paulina Kucharzewska; Tomasz P. Rygiel; Magdalena Krol
Source: Nature Communications, Vol 16, Iss 1, Pp 1-30 (2025)
Publisher Information: Nature Portfolio
Publication Year: 2025
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: Science
Description: Treatment of solid tumors remains challenging and therapeutic strategies require continuous development. Tumor-infiltrating macrophages play a pivotal role in tumor dynamics. Here, we present a Macrophage-Drug Conjugate (MDC) platform technology that enables loading macrophages with ferritin-drug complexes. We first show that macrophages actively take up human heavy chain ferritin (HFt) in vitro via macrophage scavenger receptor 1 (MSR1). We further manifest that drug-loaded macrophages transfer ferritin to adjacent cancer cells through a process termed ‘TRAnsfer of Iron-binding protein’ (TRAIN). The TRAIN process requires direct cell-to-cell contact and an immune synapse-like structure. At last, MDCs with various anti-cancer drugs are formulated with their safety and anti-tumor efficacy validated in multiple syngeneic mice and orthotopic human tumor models via different routes of administration. Importantly, MDCs can be prepared in advance and used as thawed products, supporting their clinical applicability. This MDC approach thus represents a promising advancement in the therapeutic landscape for solid tumors.
Document Type: article in journal/newspaper
Language: English
Relation: https://doi.org/10.1038/s41467-025-56637-9; https://doaj.org/toc/2041-1723; https://doaj.org/article/83a00daf9f684896b6cb93db039be5d4
DOI: 10.1038/s41467-025-56637-9
Availability: https://doi.org/10.1038/s41467-025-56637-9; https://doaj.org/article/83a00daf9f684896b6cb93db039be5d4
Accession Number: edsbas.2BB9F9A5
Database: BASE